IBI3032
Phase 1Small molecule
IBI3032 is one of 76 small molecule programs targeting Overweight. It is currently in Phase 1.
2
Indications
4
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
91 competitors in ART
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Venclexta
AbbViePhase 3
Rituxan
RochePhase 3
Brukinsa
BBeOne Medicines
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Vyvgart
ArgenxPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overweight1 trial
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
Active, not recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 1·NCT07170319·79 enrolled
Overweight or Obesity1 trial
A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After a Single Ascending Dose in Healthy Participants and After Multiple Ascending Doses in Participants With Overweight or Obesity
Completed·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 1·NCT07160400·80 enrolled
Unspecified1 trial
A Study of IBI3032 in Chinese Healthy Subjects
Completed·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 1·NCT07134127·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI3032. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details